Publications

Access hundreds of peer-reviewed cognitive research papers published by leading neuroscientists using Cogstate technology.

Search

Tag
Author
Journal
Year

Nonvascular retinal imaging markers of preclinical Alzheimer’s disease.

Authors: Alber J, Fernández B, Johnson LN, Lim YY, Maruff P, Santos CY, Snyder PJ

Journal: Alzheimer's & Dementia

Volume & Issue: 4

Page No.: 169-178

Year Published: 2016

INTRODUCTION: In patients with Alzheimer’s disease (AD) and mild cognitive impairment, structural changes in the retina (i.e., reduced thicknesses of the ganglion cell and retinal nerve fiber layers and inclusion bodies that appear to contain beta-amyloid protein [Ab]) have been previously reported. We sought to explore whether anatomic retinal changes are detectable in the preclinical […]

Corrigendum: Corrigendum to ‘Self and informant memory concerns align in healthy memory complainers and in early stages of mild cognitive impairment but separate with increasing cognitive impairment’.

Authors: Ames D, Buckley R, Ellis K, Macaulay LS, Martins R, Maruff P, Masters C, Rainey-Smith S, Rembach A, Rowe C, Saling M, Savage G

Journal: Age and Ageing

Volume & Issue: 44 & 6

Page No.: 1012-9

DOI: 10.1093/ageing/afv136

Year Published: 2016

BACKGROUND: Information provided by an informant about a patient with cognitive change is an essential component of clinical history taking. How an informant’s report relates to the patient’s phenomenological experience of memory loss is yet to be understood. The aim was to examine patterns of relationships between self and informant reports from a phenomenological perspective. […]

Amyloid burden and incident depressive symptoms in cognitively normal older adults.

Authors: Ames D, Gould E, Harrington KD, Lim YY, Martins RN, Maruff P, Masters CL, Pietrzak RH, Rainey-Smith S, Rembach A, Rowe CC, Salvado O, Villemagne VL

Journal: International Journal of Geriatric Psychiatry

DOI: 10.1002/gps.4489

Year Published: 2016

OBJECTIVE: Several studies have reported that non-demented older adults with clinical depression show changes in amyloid-β (Aβ) levels in blood, cerebrospinal fluid and on neuroimaging that are consistent with those observed in patients with Alzheimer’s disease. These findings suggest that Aβ may be one of the mechanisms underlying the relation between the two conditions. We […]

Influence of amyloid and apolipoprotein E on cognitive performance in a late middle-aged cohort.

Authors: Christianson TJ, Hagen CE, Jack CR Jr, Knopman DS, Kremers WK, Lowe VJ, Machulda MM, Mielke MM, Petersen RC, Roberts RO, Vemuri P

Journal: Alzheimer's & Dementia

DOI: 10.1016/j.jalz.2015.09.010.

Year Published: 2015

INTRODUCTION: Few studies have examined the effects of amyloid and apolipoprotein E (APOE) genotype on cognition among middle-aged individuals. METHODS: We included 464 cognitively normal, test-naïve, participants with Pittsburgh compound B positron emission tomography amyloid imaging, mean age of 62.7 (range, 51-71 years), enrolled in the Mayo Clinic Study of Aging. Participants completed multiple cognitive […]

Self and informant memory concerns align in healthy memory complainers and in early stages of mild cognitive impairment but separate with increasing cognitive impairment.

Authors: Ames D, Buckley R, Ellis K, Macaulay LS, Martins R, Maruff P, Masters C, Rainey-Smith S, Rembach A, Rowe C, Saling M, Savage G

Journal: Age and Ageing

Volume & Issue: 44 & 6

Page No.: 1012-9

DOI: 10.1093/ageing/afv136

Year Published: 2015

BACKGROUND: Information provided by an informant about a patient with cognitive change is an essential component of clinical history taking. How an informant’s report relates to the patient’s phenomenological experience of memory loss is yet to be understood. The aim was to examine patterns of relationships between self and informant reports from a phenomenological perspective. […]

Longitudinal cognitive decline in the AIBL cohort: The role of APOE ε4 status.

Authors: Albrecht MA, Ames D, Ellis KA, Foster JK, Lautenschlager NT, Martins R, Maruff P, Masters CL, Savage G, Szoeke C, Taddei K

Journal: Neuropsychologia

Volume & Issue: 75

Page No.: 411-419

DOI: 10.1016/j.neuropsychologia.2015.06.008

Year Published: 2015

The ε4 polymorphism of the APOE gene confers a substantially increased risk of developing Alzheimer’s disease. However, the influence of the ε4 allele on age-related cognitive functioning is more contentious. Previously, we demonstrated relatively little evidence for a role of the ε4 allele on baseline cognitive performance in older adults in the Australian Imaging, Biomarkers […]

The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function.

Authors: Dowling NM, Gleason CE, Jagust WJ, Johnson SC

Journal: NeuroImage

Volume & Issue: 105

Page No.: 357-68

DOI: 10.1016/j.neuroimage.2014.10.050

Year Published: 2015

Positive cerebrospinal fluid (CSF) biomarkers of tau and amyloid beta42 suggest possible active underlying Alzheimer’s disease (AD) including neurometabolic dysfunction and neurodegeneration leading to eventual cognitive decline. But the temporal relationship between CSF, imaging markers of neural function, and cognition has not been described. Using a statistical mediation model, we examined relationships between cerebrospinal fluid […]

Assessing cognition and function in Alzheimer’s disease clinical trials: do we have the right tools?

Authors: Bain L, Brannan S, Carrillo MC, Caselli RJ, Chandler J, DeSanti S, Grundman M, Isaac M, Kahle-Wrobleski K, Miller DS, Morrison G, Ryan JM, Schindler RJ, Snyder PJ

Journal: Alzheimer's & Dementia

Volume & Issue: 10 & 6

Page No.: 853-60

DOI: 10.1016/j.jalz.2014.07.158

Year Published: 2014

Several lines of evidence from Alzheimer’s disease (AD) research continue to support the notion that the biological changes associated with AD are occurring possibly several decades before an individual will experience the cognitive and functional changes associated with the disease. The National Institute on Aging-Alzheimer’s Association revised criteria for AD provided a framework for this […]

Trajectories of memory decline in preclinical Alzheimer’s disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing

Authors: Ames D, Harrington K, Laws SM, Lim YY, Martins RN, Maruff P, Masters CL, Pietrzak RH, Rembach A, Restrepo C, Rowe CC, Villemagne VL

Journal: Neurobiology of Aging

Volume & Issue: 36 & 3

Page No.: 1231-8

DOI: 10.1016/j.neurobiolaging.2014.12.015

Year Published: 2015

Memory changes in preclinical Alzheimer’s disease (AD) are often characterized by heterogenous trajectories. However, data regarding the nature and determinants of predominant trajectories of memory changes in preclinical AD are lacking. We analyzed data from 333 cognitively healthy older adults who participated in a multicenter prospective cohort study with baseline and 18-, 36-, and 54-month […]

Amyloid-β, Anxiety, and Cognitive Decline in Preclinical Alzheimer Disease: A Multicenter, Prospective Cohort Study

Authors: Ames D, Ellis KA, Harrington K, Lautenschlager NT, Lim YY, Martins RN, Maruff P, Masters CL, Neumeister A, Pietrzak RH, Restrepo C, Rowe CC, Villemagne VL

Journal: JAMA Psychiatry

Volume & Issue: 72 & 3

Page No.: 284-91

DOI: 10.1001/jamapsychiatry.2014.2476.

Year Published: 2015

IMPORTANCE: Alzheimer disease (AD) is now known to have a long preclinical phase in which pathophysiologic processes develop many years, even decades, before the onset of clinical symptoms. Although the presence of abnormal levels of amyloid-β (Aβ) is associated with higher rates of progression to clinically classified mild cognitive impairment or dementia, little research has […]

Subjective cognitive complaints contribute to misdiagnosis of mild cognitive impairment.

Authors: Bondi MW, Delano-Wood L, Edmonds EC, Galasko DR, Salmon DP

Journal: Journal of the International Neuropsychological Society

Volume & Issue: 20 & 8

Page No.: 836-47

DOI: 10.1017/S135561771400068X

Year Published: 2014

Subjective cognitive complaints are a criterion for the diagnosis of mild cognitive impairment (MCI), despite their uncertain relationship to objective memory performance in MCI. We aimed to examine self-reported cognitive complaints in subgroups of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) MCI cohort to determine whether they are a valuable inclusion in the diagnosis of MCI […]

Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer’s disease.

Authors: Klunk WE, Maruff P, Masters CL, Mathis CA, Moss SA, Ng S, Pike KE, Rowe CC, Savage G, Villemagne VL

Journal: Brain

Volume & Issue: 130 (Pt 11)

Page No.: 2837-44

Year Published: 2007

Beta-amyloid (Abeta) deposition is pathognomic for Alzheimer’s disease (AD), but may occur in normal elderly people without apparent cognitive effect. Episodic memory impairment is an early and prominent sign of AD, but its relationship with Abeta burden in non-demented persons and in AD patients is unclear. We examined this relationship using 11C-PIB-PET as a quantitative […]

Immediate and delayed effects of cognitive interventions in healthy elderly: a review of current literature and future directions.

Authors: Papp KV, Snyder PJ, Walsh SJ

Journal: Alzheimer's & Dementia

Volume & Issue: 5 & 1

Page No.: 50-60

DOI: 10.1016/j.jalz.2008.10.008

Year Published: 2009

BACKGROUND: Research on the potential effects of cognitive intervention in healthy elderly has been motivated by (1) the apparent effectiveness of cognitive rehabilitation in Alzheimer’s disease (AD) patients; (2) the face validity of bolstering skills eventually burdened by disease; (3) interest in low-cost/noninvasive methods of preventing or delaying onset of disease; (4) the epidemiologic research […]

Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: Implications for sequence of pathological events in Alzheimer’s disease.

Authors: Boeve BF, Gunter JL, Jack CR Jr, Kemp BJ, Knopman DS, Lowe VJ, Petersen RC, Senjem ML, Shiung MM, Weigand SD, Weiner M, Wiste HJ

Journal: Brain

Volume & Issue: 132 (Pt 5)

Page No.: 1355-65

DOI: 10.1093/brain/awp062

Year Published: 2009

The purpose of this study was to use serial imaging to gain insight into the sequence of pathologic events in Alzheimer’s disease, and the clinical features associated with this sequence. We measured change in amyloid deposition over time using serial (11)C Pittsburgh compound B (PIB) positron emission tomography and progression of neurodegeneration using serial structural […]

The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: Methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer’s disease.

Authors: Ames D, Bush AI, Darby D, De Fazio D, Ellis KA, Foster J, Hudson P, Lautenschlager NT, Lenzo N, Martins RN, Maruff P, Masters C, Milner A, Pike K, Rowe C, Savage G, Szoeke C, Taddei K, Villemagne V, Woodward M

Journal: International Psychogeriatrics

Volume & Issue: 21 & 4

Page No.: 672-87

DOI: 10.1017/S1041610209009405

Year Published: 2009

BACKGROUND: The Australian Imaging, Biomarkers and Lifestyle (AIBL) flagship study of aging aimed to recruit 1000 individuals aged over 60 to assist with prospective research into Alzheimer’s disease (AD). This paper describes the recruitment of the cohort and gives information about the study methodology, baseline demography, diagnoses, medical comorbidities, medication use, and cognitive function of […]

1 2 3